CRC Research Update — May 25, 2026
Today's colorectal cancer research highlights
metastatic
A collection of 12 issues
KRAS G12D-targeted therapy tested in preclinical models
Skip to content
The CRC Digest
KRAS G12D-targeted therapy tested in preclinical models
A nanomedicine delivering a KRAS G12D inhibitor showed promise in laboratory models of metastatic colorectal cancer. (Journal of Controlled Release)
This content is informational only and does not constitute medical advice.
Always consult your oncologist or care
RAS/BRAF wild-type patients: Maintenance strategies compared
Skip to content
The CRC Digest
RAS/BRAF wild-type patients: Maintenance strategies compared
Three trials pooled data on left-sided, RAS/BRAF wild-type metastatic CRC to compare toxicity profiles of different maintenance approaches. (Journal of the National Cancer Institute)
This content is informational only and does not constitute medical advice.
Always
CRC Research Finding
Skip to content
The CRC Digest
◇ Experimental nanomedicine targets KRAS G12D mutation in metastatic colorectal cancer
Preclinical research describes a macrophage-hitchhiking delivery system combining gemcitabine and a KRAS G12D inhibitor that improved drug delivery to lung metastases and triggered immune responses in colorectal cancer models. (Journal of Controlled Release)
This
CRC Research Update — May 24, 2026
Today's colorectal cancer research highlights
CRC Research Finding
Skip to content
The CRC Digest
◆ Updated survival analysis for bevacizumab in metastatic CRC
(Clinical Colorectal Cancer)
This content is informational only and does not constitute medical advice.
Always consult your oncologist or care team.
© 2026 The CRC Digest —
crcdigest.com
CRC Research Update — May 13, 2026
Today's colorectal cancer research highlights
CRC Research Update — May 12, 2026
Today's colorectal cancer research highlights
Prolonged Response to Pembrolizumab in BRAF V600E MSS Colorectal Cancer
Skip to content
The CRC Digest
Prolonged Response to Pembrolizumab in BRAF V600E MSS Colorectal Cancer
A patient with BRAF V600E-mutant microsatellite-stable metastatic colorectal cancer achieved a prolonged response to pembrolizumab following a dynamic increase in tumor mutational burden. (The Oncologist)
This content is informational only and does not constitute
CRC Research Finding
Skip to content
The CRC Digest
◆ Sequential vs. Upfront Oxaliplatin in Metastatic Colorectal Cancer: Long-Term Results
(Communications Medicine)
This content is informational only and does not constitute medical advice.
Always consult your oncologist or care team.
© 2026 The CRC Digest —
crcdigest.com